← SynDRA
GUADECITABINE
SynDRA canonical compound SYN0038171 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | DNMT1 | DNMT3A | DNMT3B | DNMT3L |
|---|
| Mechanism of action | DNA methyltransferase inhibitor |
|---|
All known targets
- DNMT1
- DNMT3A
- DNMT3B
- DNMT3L
Mechanisms of action (all sources)
- DNMT inhibitor
- DNMT1 INHIBITOR
- DNMT3A INHIBITOR
- DNA (cytosine-5)-methyltransferase 3A inhibitor
- DNA (cytosine-5)-methyltransferase 1 inhibitor
Drug classes
- Antineoplastic Agents
- Nucleic Acid Synthesis Inhibitors
- Antimetabolites
- Antimetabolites, Antineoplastic
- Enzyme Inhibitors
- Noxae
- Nucleoside Metabolic Inhibitor
ATC classes
Cross-references
Synonyms
- Guadecitabina
- Sgi-110 free acid
- SGI-110
- UNII-2KT4YN1DP7
- 2KT4YN1DP7
- SGI-110 free acid
- Guadecitabine [USAN:INN]
- GuadecitabineSGI-110
- Guadecitabine (USAN/INN)
- CHEMBL3544916
- Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-
- ZINC43203165
- AKOS027321496
- AKOS030238181
- DB11918
- CS-3089
- HY-13542
- D10877
- 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine
- guadecitabinum
- RefChem:782753
- DNMT inhibitor SGI-110
- SGI 110
- SGI-110Guadecitabine
- GUADECITABINE [INN]
- GUADECITABINE [USAN]
- GUADECITABINE [WHO-DD]
- orb1706640
- SCHEMBL20581350
- SCHEMBL23358434
- CHEBI:231603
- EX-A4647
- DA-67560
- NS00072556
- T16876
- G14403
- GUADECITABINE SODIUM [WHO-DD]
- SCHEMBL29412240
Reported adverse events
- Infection
- Headache
- Nausea
- Vomiting
- Pneumonia
- Pyrexia
- Stomatitis
- Aspartate aminotransferase
- Constipation
- Cough
- Epistaxis
- Fatigue
Look up GUADECITABINE in the interactive SynDRA portal →